Javascript must be enabled to continue!
A dosimetric comparison of versus for HDR prostate brachytherapy
View through CrossRef
For the purpose of evaluating the use of for prostate High Dose Rate brachytherapy (HDR), a hypothetical source is assumed with the exact same design of the new microSelectron source replacing the active core by pure metal. Monte Carlo simulation is employed for the full dosimetric characterization of both sources and results are compared following the AAPM TG‐43 dosimetric formalism. Monte Carlo calculated dosimetry results are incorporated in a commercially available treatment planning system , which features an inverse treatment planning option based on a multiobjective dose optimization engine. The quality of prostate HDR brachytherapy using the real and hypothetical source is compared in a comprehensive analysis of different prostate implants in terms of the multiobjective dose optimization solutions as well as treatment quality indices such as Dose Volume Histograms (DVH) and the Conformal Index (COIN). Given that scattering overcompensates for absorption in intermediate photon energies and distances in the range of interest to prostate HDR brachytherapy, proves at least equivalent to irrespective of prostate volume. This has to be evaluated in view of the shielding requirements for the energies that are minimal relative to that for .
Title: A dosimetric comparison of versus for HDR prostate brachytherapy
Description:
For the purpose of evaluating the use of for prostate High Dose Rate brachytherapy (HDR), a hypothetical source is assumed with the exact same design of the new microSelectron source replacing the active core by pure metal.
Monte Carlo simulation is employed for the full dosimetric characterization of both sources and results are compared following the AAPM TG‐43 dosimetric formalism.
Monte Carlo calculated dosimetry results are incorporated in a commercially available treatment planning system , which features an inverse treatment planning option based on a multiobjective dose optimization engine.
The quality of prostate HDR brachytherapy using the real and hypothetical source is compared in a comprehensive analysis of different prostate implants in terms of the multiobjective dose optimization solutions as well as treatment quality indices such as Dose Volume Histograms (DVH) and the Conformal Index (COIN).
Given that scattering overcompensates for absorption in intermediate photon energies and distances in the range of interest to prostate HDR brachytherapy, proves at least equivalent to irrespective of prostate volume.
This has to be evaluated in view of the shielding requirements for the energies that are minimal relative to that for .
Related Results
Nasopharyngeal intracavitary brachytherapy
Nasopharyngeal intracavitary brachytherapy
AbstractBACKGROUNDLocally persistent nasopharyngeal carcinoma (NPC) carries an increased risk of local failure if additional treatment is not given. It has been shown that intracav...
Prostatic artery embolization as a method for prevention of infravesical obstruction after low-dose-rate brachytherapy
Prostatic artery embolization as a method for prevention of infravesical obstruction after low-dose-rate brachytherapy
BACKGROUND: Infravesical obstruction in patients with localized prostate cancer caused by concomitant benign prostatic hyperplasia substantially limits the feasibility of low-dose-...
TH‐SAM‐BRB‐01: HDR and LDR Brachytherapy: Everything You Need to Know
TH‐SAM‐BRB‐01: HDR and LDR Brachytherapy: Everything You Need to Know
The development of Brachytherapy began about 1899 following the purification of radium by Pierre and Marie Curie and has been developing rapidly and continually since. The focus of...
Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial
Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia: A randomized controlled trial
Objective
To evaluate the safety, efficacy and cost‐effectiveness of holmium enucleation of the prostate and bipolar transurethral enucleation of the prostate.
...
High-dose external BEAM intensity-modulated radiotherapy (HD-IMRT) versus intensity-modulated radiotherapy plus HDR brachytherapy boost (LD-IMRT+HDR-B) dose escalation for intermediate- or high-risk prostate cancer
High-dose external BEAM intensity-modulated radiotherapy (HD-IMRT) versus intensity-modulated radiotherapy plus HDR brachytherapy boost (LD-IMRT+HDR-B) dose escalation for intermediate- or high-risk prostate cancer
263 Background: To report early & late toxicity & biochemical outcome in a prospective series of 1,465 patients with intermediate- or high-risk clinically localized prosta...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Dose-escalated adaptive image-guided radiotherapy versus high-dose-rate brachytherapy monotherapy for low-risk prostate cancer.
Dose-escalated adaptive image-guided radiotherapy versus high-dose-rate brachytherapy monotherapy for low-risk prostate cancer.
145 Background: Both IGRT and HDR are used for definitive treatment of low-risk prostate. No comparative study of these contemporary modalities exists. Methods: Charts for patient...
Brachytherapy‐related dysuria
Brachytherapy‐related dysuria
OBJECTIVE
To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy‐relat...

